PEG-IFN-alpha-2a therapy in patients with myelofibrosis: a study of the French Groupe d'Etudes des Myelofibroses (GEM) and France Intergroupe des syndromes Myéloprolifératifs (FIM).
Ianotto
Jean-Christophe
JC
Kiladjian
Jean-Jacques
JJ
Demory
Jean-Louis
JL
Roy
Lydia
L
Boyer
Françoise
F
Rey
Jerôme
J
Dupriez
Brigitte
B
Berthou
Christian
C
Abgrall
Jean-François
JF
D000328:Adult; D000368:Aged; D005260:Female; D006401:Hematologic Agents / Q000627:therapeutic use*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D055728:Primary Myelofibrosis / Q000188:drug therapy*; D011994:Recombinant Proteins
D006401:Hematologic Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; C100416:peginterferon alfa-2a